Navigation Links
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Date:10/26/2008

HIV protease representing a conserved atomic substructure that cannot be altered by mutations. This conserved substructure then served as the target for a series of protease inhibitors in development at Sequoia. SPI-256 emerged from this series of protease inhibitors as the lead candidate and was advanced to clinical studies.

In vitro activity data were also presented in this poster. These data demonstrated how the structural design elements of SPI-256 present a high genetic barrier to the emergence of resistant strains of HIV. Additionally, the unique structural properties of SPI-256 explain its high potency when tested against a panel of 50 viral strains in a PhenoSense (TM) assay. In this analysis, SPI-256 achieved potency levels 4- to 50-fold higher than currently approved front-line protease inhibitors when tested in wild-type HIV strains.

SPI-256 also exhibited an excellent resistance profile against multi-drug resistant (MDR) isolates. In an analysis of 11 "worst case scenario" MDR isolates (defined as 6 primary PI mutations and FC>50), SPI-256 retained low nanomolar activity against most MDR isolates and mean IC50 at least an order of magnitude lower than that for atazanavir, lopinavir, amprenavir, tipranavir and other reference PIs and was better than or comparable with darunavir.

Furthermore, an additional analysis demonstrated that SPI-256 possesses a high barrier to resistance. Through in vitro resistance selection experiments, when scientists at Sequoia attempted to propagate HIV in the presence of SPI-256, the drug posed a markedly higher barrier to developing resistance than atazanavir and lopinavir. Resistance to SPI-256 required the accumulation of multiple primary protease mutations.

"There is a compelling need for new protease inhibitors that potently subdue prevalent strains of HIV and which impede the development of new multi-drug resistant strains, without conferring toxicity," said John Erickson, PhD, cofounder and
'/>"/>

SOURCE Sequoia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Research explores data on ... also   to   be presented ... the global specialty biopharmaceutical company, announces that it will ... American Psychiatric Association (APA) 166th Annual Meeting in ... being presented represent Shire,s ongoing commitment to the clinical ...
(Date:5/17/2013)... Rico , May 17, 2013  Serving a region ... Puerto Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... radiation therapy capabilities with the acquisition of an Elekta Versa ... . Versa HD offers clinicians the versatility to deliver conventional ... body, while also enabling treatment of highly complex cancers that ...
(Date:5/17/2013)... Inc. (NASDAQ: ATOS ), The Breast Health Company™, ... Financial Officer & General Counsel, will present at the Second ... in New York City at the ... scheduled to begin at 3:30 p.m. EDT and will be ... to www.atossagenetics.com . For more information and ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3
... Calif., Oct. 20 Genoptix, Inc. (Nasdaq: ... that it ranked number 41 on Technology Fast 500™, ... media, telecommunications, life sciences and clean technology companies in ... year revenue growth during the five year period from ...
... Stryker Corporation (NYSE: SYK ) reported operating results ... Third Quarter Highlights Net ... reported) to $1,768 million Orthopaedic Implants sales increased 1.3% ... MedSurg Equipment sales increased 16.3% on a constant currency basis ...
Cached Medicine Technology:Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 2Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™ 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8
(Date:5/18/2013)... of coffee is associated with a reduced risk ... disease, Mayo Clinic research shows. The findings were ... conference in Orlando, Fla. , PSC is ... results in inflammation and subsequent fibrosis that can ... and biliary cancer. , "While rare, PSC has ...
(Date:5/18/2013)... 18, 2013 Assisted living and ... to safety and comfort of their residents. Systems ... clients with an effective and cost-efficient solution – ... an integrated, turnkey communications solution that helps nurses ... residents independence and privacy. , The VisionLink ...
(Date:5/18/2013)... Today, Zane Benefits, Inc. published ... in Marketplaces . Zane Benefits, which provides comprehensive ... benefits, is the leader in health care reform, ... arrangements . , According to Zane Benefits’ website, ... recently released a much-anticipated statement and Q&A on ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... “World Healthcare IT Market: Trends & Forecast (2010 – ... and opportunities in North America, Europe, Asia, & Rest ... 89 market data tables , 20 ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers will ... IT market is expected to grow from $99.6 billion ...
Breaking Medicine News(10 mins):Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3
... More than half taking naftidrofuryl, a blood vessel ... 14 (HealthDay News) -- The prescription drug naftidrofuryl ... and enables patients to walk farther, according to ... 1,266 people with the painful condition called intermittent ...
... might add to traditional risk factors , , WEDNESDAY, May 14 ... predicted the risk of death from cardiovascular disease in a ... just a preliminary finding in a long process that might ... in addition to well-established risk factors such as high blood ...
... May 14 Learning about life, health,disability and ... LIFE Foundation unveiled a significantly enhanced version of ... Web address at, http://www.lifehappens.org . The LIFE site ... with objective, easy-to-understand educational,content on all the major ...
... Proposals Reflect Ideas Championed by NCPA,s Family Policy ... embarked,in a new direction aimed at helping working ... Representatives announced a slate of legislation aimed,at simplifying ... laws. The,legislation, titled the American Families Agenda, contains ...
... are estimated to be affected by the devastation caused ... by researchers from the Johns Hopkins Bloomberg School of ... Systems (GIS), the researchers calculated the likely distribution of ... developed maps of the regions at greatest risk from ...
... Offers Precision Laser Technology for Custom Contouring of Women,s ... ... Syneron,s LipoLite, an FDA approved,minimally invasive procedure used to liquefy and remove ... United States at Ariana,Cosmetic Surgery & Laser Center in Las Vegas. LipoLite ...
Cached Medicine News:Health News:Common Drug Eases Leg Pain From Walking 2Health News:Biomarkers Predict Heart Deaths 2Health News:Biomarkers Predict Heart Deaths 3Health News:LIFE Foundation Launches Lifehappens.org to Help Consumers Make Smart Insurance-Buying Decisions 2Health News:LIFE Foundation Launches Lifehappens.org to Help Consumers Make Smart Insurance-Buying Decisions 3Health News:New Initiatives Provide Flexibility, Fairness for Families 2Health News:Estimated 3.2 million Burmese potentially affected by cyclone 2Health News:Las Vegas Plastic Surgeons First in U.S. to Offer LipoLite 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: